Medigen Vaccine Biologics (6547) — Cash Flow-to-Debt Ratio
Medigen Vaccine Biologics (6547) has a Cash Flow-to-Debt Ratio of -0.08x as of June 2026, meaning its operating cash flow of NT$-91.20 Million could theoretically repay 0% of its total liabilities (NT$1.21 Billion) in one year. See financial flexibility index of Medigen Vaccine Biologics to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Medigen Vaccine Biologics Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Medigen Vaccine Biologics across 14 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Medigen Vaccine Biologics.
Annual Cash Flow-to-Debt Ratio for Medigen Vaccine Biologics (2012–2025)
Year-by-year debt coverage analysis for Medigen Vaccine Biologics. Check Medigen Vaccine Biologics cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.11x | NT$-49.09 Million | NT$454.64 Million | ▼ -236.2% |
| 2024 | 0.08x | NT$40.75 Million | NT$513.92 Million | ▲ +137.3% |
| 2023 | -0.21x | NT$-477.75 Million | NT$2.25 Billion | ▲ +55.2% |
| 2022 | -0.47x | NT$-1.10 Billion | NT$2.32 Billion | ▼ -151.0% |
| 2021 | 0.93x | NT$579.89 Million | NT$622.95 Million | ▲ +155.1% |
| 2020 | -1.69x | NT$-589.97 Million | NT$349.40 Million | ▼ -232.2% |
| 2019 | -0.51x | NT$-462.65 Million | NT$910.28 Million | ▲ +18.5% |
| 2018 | -0.62x | NT$-356.33 Million | NT$571.10 Million | ▼ -76.9% |
| 2017 | -0.35x | NT$-217.03 Million | NT$615.41 Million | ▲ +24.9% |
| 2016 | -0.47x | NT$-163.37 Million | NT$347.90 Million | ▼ -167.1% |
| 2015 | 0.70x | NT$216.26 Million | NT$309.19 Million | ▲ +118.5% |
| 2014 | -3.78x | NT$-513.98 Million | NT$135.95 Million | ▼ -1.7% |
| 2013 | -3.72x | NT$-72.36 Million | NT$19.46 Million | ▼ -1404.9% |
| 2012 | -0.25x | NT$-5.47 Million | NT$22.15 Million | — |